

**4basebio PLC**

("4basebio" or the "Company")

**Result of Extraordinary General Meeting**

Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed.Â

**For further enquiries, please contact:**

<b>4basebio PLC</b>	+44 (0)12 2396 7943
Dr. Heikki Lanckriet, CEO	+44 (0)20 7213 0880
<b>Cairn Financial Advisers LLP (Nominated Adviser)</b>	+44 (0)20 7220 0500
Jo Turner / Sandy Jamieson / Ed Downes	+44 (0)20 7653 4000
<b>Cavendish Capital Markets Limited (Joint Broker)</b>	
Geoff Nash / Nigel Birks	
<b>RBC Capital Markets (Joint Broker)</b>	
Kathryn Deegan / Matthew Coakes	

**Notes to Editors**

**About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Companyâ€™s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

---

---